GIA
VRTX icon

Granite Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Granite Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-756
Closed -$206K – 175
2020
Q3 		$206K Hold
756
– – 0.04% 161
2020
Q2 		$219K Buy
+756
New +$205K 0.05% 150

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Granite Investment Advisors's VRTX Position: Q4 2020 in Review

Granite Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 756 shares — an estimated $206K sold.

Granite Investment Advisors first reported a position in VRTX in Q2 2020 and held it in 2 quarters. The position peaked at $219K in Q2 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Granite Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Granite Investment Advisors sold 756 Vertex Pharmaceuticals shares in Q4 2020, an estimated $206K.
  • Granite Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Granite Investment Advisors's Vertex Pharmaceuticals position peaked at $219K in Q2 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Granite Investment Advisors's 13F filing for Q4 2020, filed 12 Jan 2021.